ProMIS Neurosciences GAAP EPS of -$0.89 beats by $0.39
ProMIS Neurosciences reported Q3 GAAP EPS of -$0.89, exceeding estimates by $0.39. The company had $44.1M in cash as of September 30, 2026, up from $6.1M at the end of 2025, due to a $70.1M private placement. Shares rose 1.72% after hours.
How this was made
The 30-second read
Why it matters
The earnings beat and cash infusion provide short‑term positive sentiment, but the company remains loss‑making and micro‑cap, limiting broader market impact.
Market read
A modest earnings beat for a micro‑cap biotech; relevance primarily to niche investors.
What to watch
The cash increase stems from a private placement, which could dilute existing shareholders and affect future valuation.
Background
ProMIS Neurosciences reported Q3 GAAP EPS of -$0.89, a $0.39 beat, and cash of $44.1 M after a $70.1 M private placement.
Market effects
Minimal impact on the broader biotech sector; the beat is modest and company‑specific.
No discernible effect on regional markets.
Limited to investors tracking micro‑cap neuroscience stocks.
Counterpoint
The EPS beat may be a one‑off accounting adjustment; price could remain flat or decline if guidance is weak.
Key entities
- companyProMIS Neurosciences
Micro‑cap neuroscience firm reporting Q3 results.